Know Cancer

or
forgot password


Phase 4
10 Years
90 Years
Open (Enrolling)
Both
Myelodysplastic Syndromes

Thank you

Trial Information


Inclusion Criteria:



- patients 10 to 90 years old with primary or treatment-related MDS or chronic
myelomonocytic leukemia;

- International Prognostic Scoring System(IPSS) intermediate-1,intermediate-2,or high
risk;

- bone marrow blasts > 11% or <= 10% and poor cytogenetics;

- lack of an HLA-identical donor;

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2;

- adequate cardiac and hepatorenal functions.

Exclusion Criteria:

- have an HLA-identical donor

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

complete remission

Outcome Time Frame:

six months

Safety Issue:

Yes

Principal Investigator

Sheng Hui Ai, M.D

Investigator Role:

Principal Investigator

Investigator Affiliation:

Affiliated Hospital of Academy of Military Medical Sciences

Authority:

China: Ethics Committee

Study ID:

MST/MDS-307PLAH-ASH

NCT ID:

NCT01674985

Start Date:

September 2009

Completion Date:

December 2013

Related Keywords:

  • Myelodysplastic Syndromes
  • Decitabine
  • microtransplantation
  • myelodysplastic syndromes
  • chemotherapy
  • Myelodysplastic Syndromes
  • Preleukemia

Name

Location